Orchard Cash Pile Set To Rise With Nasdaq IPO
Executive Summary
The UK gene therapy firm was only set up in 2016 but after raising $260m in two financing rounds since the end of 2017, Orchard has filed documents with a view to listing on NASDAQ.
Topics
- Subjects
- Financing
- Rare Diseases
- Clinical Trials
- Commercial
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC123955
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
SC123955
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.